- Home
- SHMD vs CRVS Comparison
SHMD vs CRVS Comparison
Compare SHMD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- CRVS
- Stock Information
- Founded
- SHMD 1864
- CRVS 2014
- Country
- SHMD Germany
- CRVS United States
- Employees
- SHMD N/A
- CRVS N/A
- Industry
- SHMD
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- CRVS Health Care
- Exchange
- SHMD Nasdaq
- CRVS Nasdaq
- Market Cap
- SHMD 179.1M
- CRVS 459.0M
- IPO Year
- SHMD N/A
- CRVS 2016
- Fundamental
- Price
- SHMD $3.85
- CRVS $6.90
- Analyst Decision
- SHMD
- CRVS Strong Buy
- Analyst Count
- SHMD 0
- CRVS 4
- Target Price
- SHMD N/A
- CRVS $13.75
- AVG Volume (30 Days)
- SHMD 91.4K
- CRVS 1.0M
- Earning Date
- SHMD 01-01-0001
- CRVS 11-11-2025
- Dividend Yield
- SHMD N/A
- CRVS N/A
- EPS Growth
- SHMD N/A
- CRVS N/A
- EPS
- SHMD N/A
- CRVS N/A
- Revenue
- SHMD $85,165,542.00
- CRVS N/A
- Revenue This Year
- SHMD N/A
- CRVS N/A
- Revenue Next Year
- SHMD N/A
- CRVS N/A
- P/E Ratio
- SHMD N/A
- CRVS N/A
- Revenue Growth
- SHMD N/A
- CRVS N/A
- 52 Week Low
- SHMD $1.86
- CRVS $2.54
- 52 Week High
- SHMD $4.50
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- SHMD 61.51
- CRVS 50.50
- Support Level
- SHMD $3.58
- CRVS $6.90
- Resistance Level
- SHMD $4.50
- CRVS $7.98
- Average True Range (ATR)
- SHMD 0.62
- CRVS 0.56
- MACD
- SHMD 0.12
- CRVS -0.08
- Stochastic Oscillator
- SHMD 64.23
- CRVS 28.93
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).